Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
Regeneron Pharmaceuticals
Meagan P O'Brien; Eduardo Forleo-Neto; Neena Sarkar; Flonza Isa; Peijie Hou; Kuo-Chen Chan; Bret J Musser; Katharine J Bar; Ruanne V Barnabas; Dan H Barouch; Myron S Cohen; Christopher B Hurt; Dale R Burwen; Mary A Marovich; Elizabeth R Brown; Ingeborg Heirman; John D Davis; Kenneth C Turner; Divya Ramesh; Adnan Mahmood; Andrea T Hooper; Jennifer D Hamilton; Yunji Kim; Lisa A Purcell; Alina Baum; Christos A Kyratsous; James Krainson; Richard Perez-Perez; Rizwana Mohseni; Bari Kowal; A Thomas DiCioccio; Gregory P Geba; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos; David M Weinreich; COVID-19 Phase 3 Prevention Trial Team
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.